Development or Exacerbation of Head and Neck Dermatitis in Patients Treated for Atopic Dermatitis With Dupilumab - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue JAMA Dermatology Année : 2019

Development or Exacerbation of Head and Neck Dermatitis in Patients Treated for Atopic Dermatitis With Dupilumab

Résumé

The efficacy and safety of dupilumab, a humanized monoclonal antibody targeting the α subunit of the interleukin (IL)-4 and IL-13 receptors, has been assessed in adults with moderate-to-severe atopic dermatitis (AD).1,2 Injection site reactions, nasopharyngitis, conjunctivitis, and transient increases in eosinophil counts from baseline were higher in the dupilumab groups than in the placebo groups in pivotal studies.1,2 A recent study by Zhu et al3 reported new regional dermatoses in 17 patients with AD treated with dupilumab, with facial area involvement in 14 cases, whereas Blauvelt et al4 reported an equal improvement of AD with dupilumab on different anatomic regions in a post hoc analysis of data extracted from 4 phase 3 clinical trials.

Domaines

Dermatologie

Dates et versions

hal-02563178 , version 1 (05-05-2020)

Identifiants

Citer

Angèle Soria, Aurélie Du-Thanh, Julien Seneschal, Marie Jachiet, Delphine Staumont-Sallé, et al.. Development or Exacerbation of Head and Neck Dermatitis in Patients Treated for Atopic Dermatitis With Dupilumab. JAMA Dermatology, 2019, 155 (11), pp.1312. ⟨10.1001/jamadermatol.2019.2613⟩. ⟨hal-02563178⟩
47 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More